

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A composition comprising a complementary pair of siRNA oligomeric compounds consisting of:

a first oligomeric compound and a second oligomeric compound, wherein:

said first oligomeric compound and said second oligomeric compound are not covalently linked to each other;

~~wherein~~ at least a portion of said first oligomeric compound is ~~capable of hybridizing with~~ complementary to at least a portion of said second oligomeric compound;~~;~~

~~wherein at least a portion of said first oligomeric compound is capable of hybridizing and to a target nucleic acid, and ; and~~

wherein at least one of said first and said second oligomeric compounds comprises at least one conjugate moiety, wherein said at least one conjugate moiety is attached to a terminal monomeric subunit of said at least one oligomeric compound and wherein said at least one conjugate moiety is a steroid.

2-3. (canceled)

4. (Original) The composition of claim 1 wherein each of said first and second oligomeric compounds comprises 10 to 40 nucleotides.

5. (Original) The composition of claim 1 wherein each of said first and second oligomeric compounds comprises 18 to 30 nucleotides.

6. (Original) The composition of claim 1 wherein each of said first and second oligomeric compounds comprises 21 to 24 nucleotides.

7-8. (canceled)

9. (Currently amended) The composition of ~~claim 7~~ claim 1 wherein said second oligomeric compound comprises an oligonucleotide having a plurality of ribose nucleotide units.
10. (Original) The composition of claim 1 wherein said first oligomeric compound comprises said at least one conjugate moiety.
11. (Original) The composition of claim 1 wherein said second oligomeric compound comprises said at least one conjugate moiety.
12. (Original) The composition of claim 1 wherein said first and second oligomeric compounds each comprises at least one conjugate moiety.
13. (Original) The composition of claim 1 wherein said second oligomeric compound comprises at least one conjugate moiety and said first oligomeric compound comprises no conjugate moiety.
- 14-16. (canceled)
17. (Currently amended) The composition of ~~claim 16~~ claim 1 wherein said terminal ~~residue~~ monomeric subunit is at the 5' end of said first or second oligomeric compounds.
- 18-20. (canceled)
21. (Original) The composition of claim 1 wherein said at least one conjugate moiety is attached to said first or second oligomeric compounds through a linker.
- 22-23. (canceled)
24. (Original) The composition of claim 1 wherein said at least one conjugate moiety is cholesterol or a cholesterol derivative.

25. (Original) The composition of claim 1 wherein said at least one conjugate moiety binds to low-density lipoprotein.

26-35. (canceled)

36. (Original) The composition of claim 1 wherein said at least one conjugate moiety enhances the pharmacokinetic or pharmacodynamic properties of said composition.

37. (Original) The composition of claim 1 wherein said composition has improved cellular uptake properties compared with the same composition having no conjugate moiety.

38-100. (canceled)

101. (Original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

102-109. (canceled)